ECM
RLAY icon

ExodusPoint Capital Management’s Relay Therapeutics RLAY Stock Holding History

ExodusPoint Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,141,880
Closed -$9.66M – 2016
2025
Q4 		$9.66M Buy
+1,141,880
New +$8.15M 0.08% 266
2025
Q3 		– Sell
-170,196
Closed -$589K – 1939
2025
Q2 		$589K Buy
+170,196
New +$506K 0.01% 1111
2024
Q1 		– Sell
-82,761
Closed -$911K – 1894
2023
Q4 		$911K Buy
+82,761
New +$698K 0.01% 852
2023
Q1 		– Sell
-104,736
Closed -$1.56M – 2073
2022
Q4 		$1.56M Buy
+104,736
New +$2M 0.02% 753

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

ExodusPoint Capital Management's RLAY Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 1,141,880 shares — an estimated $9.66M sold.

ExodusPoint Capital Management first reported a position in RLAY in Q4 2022 and held it in 4 quarters. The position peaked at $9.66M in Q4 2025. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 1,141,880 Relay Therapeutics shares in Q1 2026, an estimated $9.66M.
  • ExodusPoint Capital Management first reported a position in Relay Therapeutics in Q4 2022 and held it in 4 quarters.
  • ExodusPoint Capital Management's Relay Therapeutics position peaked at $9.66M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.